Antiandrogenic Activity of Riboflavin 5′-Phosphate (FMN) in 22Rv1 and LNCaP Human Prostate Cancer Cell Lines

    January 2022 in “ European Journal of Pharmacology ”
    Yun-Ho Choi, Jaeyoon Kim, Jae Young Shin … Sang-Hwa Lee
    Studysummary In this study, FMN was found to inhibit androgen receptor function and androgen-regulated gene expression in prostate cancer cells, suggesting potential as an antiandrogen therapy.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on sciencedirect.com →
    Discuss this study in the Community →

    Research cited in this study 3

    1. Treatment of Female Pattern Hair Loss with the Androgen Receptor Antagonist Flutamide Australasian Journal of Dermatology · 2011
    2. Side Effects of Androgen Deprivation Therapy: Monitoring and Minimizing Toxicity Urology · 2003
    3. Androgen-Inducible TGF-β1 from Balding Dermal Papilla Cells Inhibits Epithelial Cell Growth: A Clue to Understanding Paradoxical Effects of Androgen on Human Hair Growth ˜The œFASEB journal · 2002